Kevin G. Shim

983 citations

28 papers · 634 indexed · h-index 13

Co-authors: Jill Thompson Richard G. Vile Alan Melcher Shane Zaidi Timothy Kottke Karishma Rajani Kevin J. Harrington Matt Coffey
Topics: Virus-based gene therapy research (11 papers)CAR-T cell therapy research (9 papers)Immunotherapy and Immune Responses (8 papers)
Cited by: Oncology Genetics Immunology
Journals: Nature Communications Blood Cancer Research
Partner nations: United States United Kingdom Canada

In The Last Decade

Kevin G. Shim

26 papers receiving 628 citations

Peers

Countries citing papers authored by Kevin G. Shim

Since Specialization

Citations

This map shows the geographic impact of Kevin G. Shim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin G. Shim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin G. Shim more than expected).

Fields of papers citing papers by Kevin G. Shim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin G. Shim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin G. Shim. The network helps show where Kevin G. Shim may publish in the future.

Co-authorship network of co-authors of Kevin G. Shim

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin G. Shim. A scholar is included among the top collaborators of Kevin G. Shim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin G. Shim. Kevin G. Shim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Brachial Gunshot Wounds: Injury Patterns and Considerations for Managing the Abnormal Neurological Examination 2024 ·Hand ·David Chi,(unknown),(unknown),(unknown),Rachael M. Payne,(unknown),Kevin G. Shim,Susan E. Mackinnon,Mitchell A. Pet	2
2	Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies 2024 ·Cancers ·Kevin G. Shim,Rafaël Fonseca	1
3	IMC-Denoise: a content aware denoising pipeline to enhance Imaging Mass Cytometry 2023 ·Nature Communications ·(unknown),Karolyn A. Oetjen,Diane E. Bender,Marianna B. Ruzinova,Daniel A.C. Fisher,Kevin G. Shim,Russell K. Pachynski,W. Nathaniel Brennen,Stephen T. Oh,Daniel C. Link,Daniel L.J. Thorek	29
4	Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice 2023 ·Experimental Hematology ·Daniel A.C. Fisher,Angelo B. A. Laranjeira,Tim Kong,(unknown),Kevin G. Shim,Mary C. Fulbright,Stephen T. Oh	1
5	Mechanism matters: A 10-year experience of ballistic injuries of the upper extremity 2023 ·Injury ·(unknown),Kevin G. Shim,(unknown),Rachael M. Payne,(unknown),David Chi,(unknown),Mitchell A. Pet	2
6	Management of acute promyelocytic leukemia in the setting of acute COVID-19 infection 2022 ·Leukemia Research Reports ·Kevin G. Shim,(unknown),Kristan Augustin,Karolyn A. Oetjen	0
7	APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy 2020 ·Nature Communications ·Christopher B. Driscoll,Matthew Schuelke,Timothy Kottke,Jill Thompson,Phonphimon Wongthida,Jason M. Tonne,Amanda L. Huff,Amber Miller,Kevin G. Shim,Amy M. Molan,Cynthia Wetmore,Peter J. Selby,Adel Samson,Kevin J. Harrington,Hardev Pandha,Alan Melcher,José S. Pulido,Reuben S. Harris,Laura Evgin,Richard G. Vile	49
8	Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses 2020 ·Molecular Therapy ·Amanda L. Huff,Laura Evgin,Jill Thompson,Tim Kottke,Christopher B. Driscoll,Jason M. Tonne,Phonphimon Wongthida,Matthew Schuelke,Kevin G. Shim,Georges Mer,Marina Ramı́rez-Alvarado,Richard G. Vile	5
9	Oncolytic virus-derived type I interferon restricts CAR T cell therapy 2020 ·Nature Communications ·Laura Evgin,Amanda L. Huff,Phonphimon Wongthida,Jill Thompson,Tim Kottke,Jason M. Tonne,Matthew Schuelke,Katayoun Ayasoufi,Christopher B. Driscoll,Kevin G. Shim,(unknown),Dileep D. Monie,Aaron J. Johnson,Matt Coffey,Sarah L. Young,Gary E. Archer,John H. Sampson,José S. Pulido,(unknown),Richard G. Vile	92
10	Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment 2019 ·Cancer Immunology Research ·Laura Evgin,Amanda L. Huff,Timothy Kottke,Jill Thompson,Amy M. Molan,Christopher B. Driscoll,Matthew Schuelke,Kevin G. Shim,Phonphimon Wongthida,Elizabeth J. Ilett,(unknown),Reuben S. Harris,Matt Coffey,José S. Pulido,Hardev Pandha,Peter J. Selby,Kevin J. Harrington,Alan Melcher,Richard G. Vile	13
11	Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity 2019 ·Journal for ImmunoTherapy of Cancer ·Matthew Schuelke,Phonphimon Wongthida,Jill Thompson,Timothy Kottke,Christopher B. Driscoll,Amanda L. Huff,Kevin G. Shim,Matt Coffey,José S. Pulido,Laura Evgin,Richard G. Vile	10
12	Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies 2018 ·Clinical Cancer Research ·Hanni Uusi-Kerttula,James A. Davies,Jill Thompson,Phonphimon Wongthida,Laura Evgin,Kevin G. Shim,Angela C. Bradshaw,Alexander T. Baker,P.J. Rizkallah,Robin L. Jones,Louise Hanna,Emma Hudson,Richard G. Vile,John Chester,Alan L. Parker	38
13	APOBEC3 Mediates Resistance to Oncolytic Viral Therapy 2018 ·Molecular Therapy — Oncolytics ·Amanda L. Huff,Phonphimon Wongthida,Timothy Kottke,Jill Thompson,Christopher B. Driscoll,Matthew Schuelke,Kevin G. Shim,Reuben S. Harris,Amy M. Molan,José S. Pulido,Peter J. Selby,Kevin J. Harrington,Alan Melcher,Laura Evgin,Richard G. Vile	19
14	Early Cannulation of Bovine Carotid Artery Graft Reduces Tunneled Dialysis Catheter-Related Complications: A Comparison of Bovine Carotid Artery Graft Versus Expanded Polytetrafluoroethylene Grafts in Hemodialysis Access 2018 ·Vascular and Endovascular Surgery ·(unknown),(unknown),(unknown),(unknown),Kevin G. Shim,Peter H. Lin	9
15	Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy 2017 ·Molecular Therapy ·Kevin G. Shim,Shane Zaidi,Jill Thompson,Tim Kottke,Laura Evgin,Karishma Rajani,Matthew Schuelke,Christopher B. Driscoll,Amanda L. Huff,José S. Pulido,Richard G. Vile	19
16	Immunogenicity of self tumor associated proteins is enhanced through protein truncation 2016 ·Molecular Therapy — Oncolytics ·Tim Kottke,Kevin G. Shim,Vanesa Alonso-Camino,Shane Zaidi,Rosa María Díaz,José S. Pulido,Jill Thompson,Karishma Rajani,Laura Evgin,Elizabeth J. Ilett,Hardev Pandha,Kevin J. Harrington,Peter J. Selby,Alan Melcher,Richard G. Vile	3
17	Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses 2015 ·Molecular Therapy ·Karishma Rajani,Christopher Parrish,Timothy Kottke,Jill Thompson,Shane Zaidi,Elizabeth J. Ilett,Kevin G. Shim,(unknown),Hardev Pandha,Kevin J. Harrington,Matt Coffey,Alan Melcher,Richard G. Vile	154
18	Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling 2015 ·Neuro-Oncology ·Julia Cockle,Karishma Rajani,Shane Zaidi,Timothy Kottke,Jill Thompson,Rosa María Díaz,Kevin G. Shim,Tim Peterson,Ian F. Parney,Susan Short,Peter J. Selby,Elizabeth J. Ilett,Alan Melcher,Richard G. Vile	57
19	Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy 2015 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown),Kevin G. Shim,Michael P. Grams,Karishma Rajani,Rosa María Díaz,Keith M. Furutani,Jill Thompson,Kenneth R. Olivier,Sean S. Park,Svetomir N. Markovic,Hardev Pandha,Alan Melcher,Kevin J. Harrington,Shane Zaidi,Richard G. Vile	16
20	Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents 2014 ·Molecular Therapy ·Shane Zaidi,(unknown),Kevin G. Shim,Elizabeth J. Ilett,Karishma Rajani,Christopher Parrish,Nicolas Boisgerault,Tim Kottke,Jill Thompson,Esteban Celis,José S. Pulido,Peter J. Selby,Hardev Pandha,Alan Melcher,Kevin J. Harrington,Richard G. Vile	11

About Kevin G. Shim

Kevin G. Shim is a scholar working on Biotechnology, Oncology and Immunology, having authored 28 papers that have together received 634 indexed citations. Recurring topics across this work include Virus-based gene therapy research (11 papers), CAR-T cell therapy research (9 papers) and Immunotherapy and Immune Responses (8 papers). The work is most often cited by research in Oncology (374 citations), Genetics (318 citations) and Immunology (215 citations). Kevin G. Shim has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Jill Thompson, Richard G. Vile, Alan Melcher, Shane Zaidi, Timothy Kottke, Karishma Rajani, Kevin J. Harrington, Matt Coffey, Hardev Pandha and Elizabeth J. Ilett. Their work appears in journals such as Nature Communications, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact